|
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
400, ERYTHROMYCIN ETHYLSUCCINATE E.E.S., ERYTHROMYCIN ETHYLSUCCINATE EC-NAPROSYN, NAPROXEN ECONAZOLE NITRATE, ECONAZOLE NITRATE ECONOCHLOR, CHLORAMPHENICOL ECONOPRED PLUS, PREDNISOLONE ACETATE ECONOPRED, PREDNISOLONE ACETATE EDECRIN, ETHACRYNATE SODIUM EDECRIN, ETHACRYNIC ACID EDETATE DISODIUM, EDETATE DISODIUM EDEX, ALPROSTADIL EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM...
|
|
|
Barr Pharmaceuticals, Inc.
Contact Us Product Guide Drug Information Site Map Key Marketed Proprietary Products - Mircette® Mircette (Desogestrel/Ethinyl Estradiol) is an oral contraceptive product that Duramed Pharmaceuticals markets under agreement with Organon USA Inc.
Mircette is a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl ...
|
|
|
Barr Pharmaceuticals, Inc.
Contact Us Product Guide Drug Information Site Map Key Marketed Proprietary Products - SEASONIQUE™ SEASONIQUE™ is an FDA approved extended-cycle oral contraceptive for the prevention of pregnancy.
The majority of oral contraceptive products currently available in the United States are based on a regimen of 21 treatment days of active ingredient and then a seven-day...
|
|
|
Barr Pharmaceuticals, Inc.
Contact Us Product Guide Drug Information Site Map Corporate Profile Barr Pharmaceuticals, Inc.
Barr’s business has two reportable segments: generic pharmaceuticals and proprietary pharmaceuticals.
These products include the SEASONIQUE™ (levonorgestrel and ethinyl estradiol) extended-cycle oral contraceptive product, ENJUVIA™ (synthetic conjugated...
|
|
|
Barr Pharmaceuticals, Inc.
Contact Us Product Guide Drug Information Site Map Corporate Profile Barr Pharmaceuticals, Inc.
Barr’s business has two reportable segments: generic pharmaceuticals and proprietary pharmaceuticals.
These products include the SEASONIQUE™ (levonorgestrel and ethinyl estradiol) extended-cycle oral contraceptive product, ENJUVIA™ (synthetic conjugated...
|
|
|
AR 2007 Lo Res.pdf
Barr now operates in over 30 countries across the world.
Duramed Pharmaceuticals is focused on proprietary pharmaceuticals in North America.
Congress.
INTERNATIONAL PRODUCT MARKETING The European generic pharmaceutical market varies considerably from country to country.
were converted from the Odyssey label to the Duramed label at year- end, and are now part of the...
|
|
|
AR 2007 Lo Res.pdf page 14
|
|
|
11744_pcepnu_nuvigil_master_14
NUVIGIL TM (armodafinil) Tablets [C-IV] Rx Only DESCRIPTION NUVIGIL TM (armodafinil) is a wakefulness-promoting agent for oral administration.
1.0% in the feces).
Evaluators were not given any specific guidance about the criteria they were to apply when rating patients.
In the NUVIGIL controlled studies, depression was also a reason for treatment discontinuation more often...
author: smelindo
duplicates:
http://www.anesta.com/newsroom/assets/Nuvigil_prescribing_information.pdf
|
|
|
11744_pcepnu_nuvigil_master_14 page 3
author: smelindo
duplicates:
http://www.anesta.com/newsroom/assets/Nuvigil_prescribing_information.pdf
|
|
|
LF-53826
DESCRIPTION Mircette ® (desogestrel/ ethinyl estradiol and ethinyl estradiol) Tablets provide an oral contraceptive regimen of 21 white tablets each containing 0.15 mg desogestrel (13- ethyl- 11- methylene- 18,19- dinor- 17 alpha- pregn- 4- en- 20- yn- 17- ol), 0.02 mg ethinyl estradiol (19- nor- 17 alpha- pregna- 1,3,5 (10)- trien- 20- yne- 3...
author: Eithne Kearns
|
|
|
LF-53826 page 2
author: Eithne Kearns
|
|
|
LF-53826 page 1
author: Eithne Kearns
|
|
|
233040 Seasonale
The risks associated with taking oral contraceptives increase significantly if you: Rx only (levonorgestrel / ethinyl estradiol tablets) 0.15 mg / 0.03 mg (levonorgestrel / ethinyl estradiol tablets) 0.15 mg / 0.03 mg (levonorgestrel / ethinyl estradiol tablets) 0.15 mg / 0.03 mg (levonorgestrel / ethinyl estradiol tablets) 0.15 mg / 0...
author: Mary
|
|
|
233040 Seasonale page 2
author: Mary
|
|
|
233040 Seasonale page 1
author: Mary
|
|
|
http://www.barrlabs.com/overview/annual/BRL_AR2001.pdf
Barr Laboratories, Inc.
In addition, we launched generic products including versions of Tylox ® , a pain management product; Cordarone ® , for recurrent ventricular arrhythmias; DextroStat ® , for narcolepsy and attention deficit disorder; and Luvox ® , used to treat Obsessive Compulsive Disorder.
This case involves raw material patents.
Downey Chairman 6...
|
|
|
http://www.barrlabs.com/overview/annual/BRL_AR2001.pdf page 15
|
|
|
http://www.barrlabs.com/overview/annual/BRL_AR2002.pdf page 49
|
|
|
Pages
Barr Laboratories, Inc.
's Provigil® (Modafinil), for patients experiencing excessive daytime sleepiness associated with narcolepsy.
Under the SEASONALE extended regimen, women take active contraceptive tablets of 0.15 mg of levonorgestrel/ 0.03 mg of ethinyl estradiol for 84 consecutive days, followed by a sevenday interval during which placebo pills are taken...
author: Lisa
|
|
|
Pages page 53
author: Lisa
|
|
|
Pages page 6
author: Lisa
|
|
|
THE MERCK MANUAL, Sec. 19, Ch. 256, Health Management In Normal Newborns, Infants, And Children
This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 19.
Weight gain < 200 to 250 g/wk (< 6 to 8 oz) in infants < age 4 mo is inadequate.
With cystic fibrosis, pancreatic insufficiency results in trypsin and lipase deficits, c ausing high fecal losses of protein and fats with consequent malnutrition and growth retardation.
The...
|
|
|
THE MERCK MANUAL, Sec. 18, Ch. 246, Family Planning
This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 18.
Ovulation usually occurs about 14 days before onset of the next menses.
New users should be given low-dose formulations with 20 to 35 µg of ethinyl estradiol, and women taking formulations with 50 µg of estrogen should usually be switched to low-dose formulations.
|
|
|
THE MERCK MANUAL, Sec. 15, Ch. 192, Psychosexual Disorders
This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 15.
Those with gender identity disorders, however, experience a severe incongruity between their anatomic sex and their gender identity.
A child with the disorder prefers cross-dressing, insists that he is of the other sex, intensely and persistently desires to participate in the stereotypical...
|
|
|
THE MERCK MANUAL, Sec. 18, Ch. 244, Medical Examination Of The Rape Victim
This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 18.
About 50% of female rape victims have signs of physical trauma; > 10% require emergency treatment.
History and physical examination: A brief description of the assault indicates areas for medical investigation and treatment; recounting the events is often frightening for the patient, and...
|
